Our present study provides strong evidence that SYNJ1 is misregulated in AD brains and points to the possibility that targeting abnormal modifications of SYNJ1 could open up new windows to novel therapeutic strategies against AD. The gene discussed is SYNJ1; the disease is Alzheimer disease.